• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Activation of c-jun N-terminal kinase upon Influenza AVirus (IAV) infection is independent of pathogen related receptors, but dependent on amino acid

tetano

Editor, Senior Moderator
J Virol. 2014 May 28. pii: JVI.00424-14. [Epub ahead of print]
Activation of c-jun N-terminal kinase upon Influenza AVirus (IAV) infection is independent of pathogen related receptors, but dependent on amino acid sequence variations of the IAV NS1.
Nacken W1, Anhlan D1, Hrincius ER1, Mostafa A2, Wolff T3, Sadewasser A3, Pleschka S4, Ehrhardt C5, Ludwig S6.
Author information
Abstract

A hallmark cell response to influenza A virus (IAV) infections is the phosphorylation and activation of c-jun N-terminal kinase (JNK). However, so far it is not fully clear which molecules are involved in the activation of JNK upon IAV infection. Here, we report that the transfection of influenza viral RNA induces JNK in a RIG-I dependent manner. However, neither RIG-I like receptors nor MyD88 dependent toll like receptors were found to be involved in the activation of JNK upon IAV infection. Viral JNK activation could be blocked by addition of cycloheximide and heat shock protein inhibitors during infection suggesting that the expression of an IAV encoded protein is responsible for JNK activation. Indeed, the over expression of the non-structural protein NS1 of certain IAV subtypes activated JNK, whereas those of some other subtypes failed to activate JNK. Site directed mutagenesis experiments using NS1 of IAV H7N7, H5N1 and H3N2 subtypes identified the amino acid (aa) residue phenylalanine (F) at position 103 to be decisive for JNK activation. The cleavage and polyadenylation specific factor 30 (CPSF30), whose binding to NS1 is stabilised by the aa F103 and M106, is not involved in JNK activation. Conclusively, subtype specific sequence variations in the IAV NS1 protein result in subtype specific differences in JNK signaling upon IAV infection.
IMPORTANCE:

Influenza A virus (IAV) infection leads to the activation or modulation of multiple signalling pathways. Here, we demonstrate for the first time, that the c-jun N-terminal kinase (JNK), a long known stress activated MAP kinase, is activated by Rig-I when cells are treated with IAV RNA. However, on the same time, the non-structural protein 1 (NS1) of IAV has an intrinsic JNK activating property that is dependent on IAV subtype specific amino acid variations around position 103. Our findings identify two different and independent pathways that result in the activation of JNK in course of an IAV infection.

Copyright ? 2014, American Society for Microbiology. All Rights Reserved.

PMID:
24872593
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24872593
 
Back
Top